CA2700173C - Methods of synthesis of certain hydroxamic acid compounds - Google Patents

Methods of synthesis of certain hydroxamic acid compounds Download PDF

Info

Publication number
CA2700173C
CA2700173C CA2700173A CA2700173A CA2700173C CA 2700173 C CA2700173 C CA 2700173C CA 2700173 A CA2700173 A CA 2700173A CA 2700173 A CA2700173 A CA 2700173A CA 2700173 C CA2700173 C CA 2700173C
Authority
CA
Canada
Prior art keywords
compound
formula
independently
reacting
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2700173A
Other languages
English (en)
French (fr)
Other versions
CA2700173A1 (en
Inventor
Helge A. Reisch
Peter Leeming
Prasad S. Raje
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Topotarget UK Ltd
Original Assignee
Topotarget UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Topotarget UK Ltd filed Critical Topotarget UK Ltd
Publication of CA2700173A1 publication Critical patent/CA2700173A1/en
Application granted granted Critical
Publication of CA2700173C publication Critical patent/CA2700173C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
    • C07C303/40—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2700173A 2007-09-25 2008-09-23 Methods of synthesis of certain hydroxamic acid compounds Active CA2700173C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97488007P 2007-09-25 2007-09-25
US60/974,880 2007-09-25
PCT/GB2008/003226 WO2009040517A2 (en) 2007-09-25 2008-09-23 Methods of synthesis of certain hydroxamic acid compounds

Publications (2)

Publication Number Publication Date
CA2700173A1 CA2700173A1 (en) 2009-04-02
CA2700173C true CA2700173C (en) 2016-10-11

Family

ID=40293778

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2700173A Active CA2700173C (en) 2007-09-25 2008-09-23 Methods of synthesis of certain hydroxamic acid compounds

Country Status (7)

Country Link
US (1) US8642809B2 (enExample)
EP (1) EP2203421B1 (enExample)
JP (1) JP2010540426A (enExample)
CN (1) CN101868446A (enExample)
CA (1) CA2700173C (enExample)
MX (1) MX2010003230A (enExample)
WO (1) WO2009040517A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
AU2010203356B2 (en) 2009-01-09 2015-11-26 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
CN102548975A (zh) * 2009-07-07 2012-07-04 安瑟生物科技私人有限公司 组蛋白去乙酰化酶抑制剂
AU2011274787B2 (en) 2010-07-07 2016-06-16 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
CN102531972A (zh) * 2010-12-31 2012-07-04 北京万全阳光医药科技有限公司 抗肿瘤药物Belinostat的中间体的制备方法
CN102786448B (zh) * 2012-08-09 2014-03-12 深圳万乐药业有限公司 一种合成belinostat的方法
AU2013305591B2 (en) 2012-08-24 2017-04-13 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
EP3068388A4 (en) 2013-11-11 2017-04-12 Board of Regents of the University of Texas System Neuroprotective compounds and use thereof
CN103724239A (zh) * 2013-12-31 2014-04-16 无锡万全医药技术有限公司 一种3-（3-苯基氨磺酰基-苯基）-丙烯酸酯的制备方法
CN103787924A (zh) * 2014-01-14 2014-05-14 北京万全德众医药生物技术有限公司 抗肿瘤药物Belinostat的一种新纯化方法
CN104478769B (zh) * 2014-12-22 2016-01-06 深圳万乐药业有限公司 一种适合工业化生产的贝利司他合成方法
CN105367455B (zh) * 2015-12-18 2017-10-24 深圳万乐药业有限公司 一种贝利司他异构体的制备方法
US11013698B2 (en) 2016-03-15 2021-05-25 Oryzon Genomics S.A. Combinations of LSD1 inhibitors for the treatment of hematological malignancies
ES3057783T3 (en) 2016-03-15 2026-03-04 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
WO2017199264A1 (en) * 2016-05-17 2017-11-23 Biophore India Pharmaceuticals Pvt. Ltd. Novel process for the preparation of belinostat
AU2017304887B2 (en) * 2016-07-26 2020-07-23 Fresenius Kabi Oncology Ltd Polymorphic forms of belinostat and processes for preparation thereof
WO2018029699A1 (en) * 2016-08-11 2018-02-15 Msn Research & Development Center Solid state forms of (2e)-n-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide and process for preparation thereof
CN106565552A (zh) * 2016-10-31 2017-04-19 瑞阳制药有限公司 贝利司他结晶体及其制备方法
US11072583B2 (en) 2017-11-27 2021-07-27 Council Of Scientific & Industrial Research Indole (sulfomyl) n-hydroxy benzamide derivatives as selective HDAC inhibitors
CN108033902B (zh) * 2017-12-26 2020-07-07 深圳万乐药业有限公司 一种高纯度贝利司他顺式异构体的制备方法
CN109265377B (zh) * 2018-10-25 2021-01-22 瑞阳制药股份有限公司 贝利司他的绿色合成方法
CN109336788A (zh) * 2018-10-31 2019-02-15 安徽省庆云医药股份有限公司 一种贝利司他的制备方法
CN111848591B (zh) * 2019-04-25 2022-03-18 成都先导药物开发股份有限公司 Hdac抑制剂及其制备方法和用途
CN115636774B (zh) * 2022-12-01 2023-12-22 南开大学 一种贝利司他的合成方法
CN119456224B (zh) * 2024-10-31 2025-11-28 郑州大学 一种矿物的预处理方法协同浮选药剂的分离工艺

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642316A (en) * 1985-05-20 1987-02-10 Warner-Lambert Company Parenteral phenytoin preparations
US6071923A (en) * 1994-09-16 2000-06-06 Bar-Ilan University Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases
US5730977A (en) 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
EP0827742A1 (en) 1996-09-04 1998-03-11 Vrije Universiteit Brussel Use of histone deacetylase inhibitors for treating fribosis or cirrhosis
TR200101049T2 (tr) * 1998-10-13 2002-01-21 Fujisawa Pharmaceutical Co. Ltd. Siklik tetrapeptid bileşiği ve kullanımı
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
IL145941A (en) * 1999-04-28 2007-08-19 Univ Texas Compositions and methods for cancer treatment by selectively inhibiting vegf
CA2391952C (en) * 1999-11-23 2012-01-31 Methylgene Inc. Inhibitors of histone deacetylase
GB0023983D0 (en) * 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
WO2002026696A1 (en) 2000-09-29 2002-04-04 Prolifix Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
JP4975941B2 (ja) * 2000-09-29 2012-07-11 トポターゲット ユーケー リミテッド （ｅ）−ｎ−ヒドロキシ−３−（３−スルファモイル−フェニル）アクリルアミド化合物及びその治療用途
JPWO2002074298A1 (ja) * 2001-03-21 2004-07-08 小野薬品工業株式会社 Ｉｌ−６産生阻害剤
ES2310213T3 (es) 2001-05-02 2009-01-01 The Regents Of The University Of California Procedimiento para tratar trastornos neurodegenerativos, psiquiatricos y otros trastornos con inhibidores de desacetilasa.
NZ531153A (en) * 2001-08-09 2005-10-28 Ono Pharmaceutical Co Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
DK1426054T3 (da) 2001-08-21 2011-12-12 Astellas Pharma Inc Medicinsk anvendelse af histon-deacetylase-inhibitor og fremgangsmåde til evaluering af antitumor virkning deraf
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
EP1293205A1 (en) 2001-09-18 2003-03-19 G2M Cancer Drugs AG Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
MXPA04006717A (es) * 2002-01-11 2004-11-10 Matthias Rath Una formulacion farmaceutica nutriente que comprende polifenoles y su uso para el tratamiento del cancer.
WO2003066889A2 (en) 2002-02-07 2003-08-14 Axys Pharmaceuticals, Inc. Assay for acytyltransferase or deacetylase activity
US20050288227A1 (en) * 2002-02-15 2005-12-29 Marks Paul A Use of thioredoxin measurements for diagnostics and treatments
EP1482962A4 (en) * 2002-02-15 2009-12-23 Sloan Kettering Inst Cancer METHOD FOR THE TREATMENT OF TRX-MEDIATED ILLNESSES
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
NZ550185A (en) * 2002-03-04 2008-10-31 Merck Hdac Res Llc Methods of inducing terminal differentiation Methods of inducing terminal differentiation
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
AU2003218737B2 (en) 2002-03-13 2008-04-10 Janssen Pharmaceutica N.V. Inhibitors of histone deacetylase
BR0308908A (pt) 2002-04-03 2005-01-04 Topotarget Uk Ltd Composto, composição, uso de um composto, e, métodos para inibir a hdac em uma célula, para o tratamento de uma condição mediada pela hdac, de um condição proliferativa, de câncer e de psorìase
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
AU2003219595A1 (en) * 2002-04-11 2003-10-27 In2Gen Co., Ltd. Alpha,Beta-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS
WO2003088954A1 (en) * 2002-04-15 2003-10-30 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
US8883148B2 (en) * 2002-04-26 2014-11-11 Asan Laboratories Company (Cayman), Limited Prevention of joint destruction
GB0209715D0 (en) 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
DE10233412A1 (de) 2002-07-23 2004-02-12 4Sc Ag Neue Verbindungen als Histondeacetylase-Inhibitoren
JP2005539001A (ja) 2002-08-02 2005-12-22 アージェンタ・ディスカバリー・リミテッド ヒストンデアセチラーゼインヒビターとしての置換チエニルヒドロキサム酸
GB0226370D0 (en) 2002-11-12 2002-12-18 Novartis Ag Organic compounds
US20080004311A1 (en) * 2002-11-12 2008-01-03 Alcon, Inc. Histone deacetylase inhibitors for treating degenerative diseases of the eye
ITMI20030025A1 (it) 2003-01-10 2004-07-11 Italfarmaco Spa Derivati dell'acido idrossammico ad attivita' antinfiammatoria.
TW200418806A (en) 2003-01-13 2004-10-01 Fujisawa Pharmaceutical Co HDAC inhibitor
WO2004064727A2 (en) 2003-01-16 2004-08-05 Georgetown University Method of cancer treatment using hdac inhibitors
TW200424174A (en) 2003-02-06 2004-11-16 Hoffmann La Roche New TP diamide
AU2003900608A0 (en) 2003-02-11 2003-02-27 Fujisawa Pharmaceutical Co., Ltd. Hdac inhibitor
US7244751B2 (en) 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
EP1597390A4 (en) 2003-02-18 2006-12-27 Maxcyte Inc LOADING CELLS WITH ANTIGENES BY ELECTROPORATION
KR20050122210A (ko) 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
TW200424187A (en) 2003-04-04 2004-11-16 Hoffmann La Roche New oxime derivatives and their use as pharmaceutically active agents
PL1611088T3 (pl) 2003-04-07 2009-11-30 Pharmacyclics Inc Hydroksamiany jako środki terapeutyczne
US20040220242A1 (en) * 2003-05-02 2004-11-04 Leland Shapiro Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
KR101351122B1 (ko) 2003-05-09 2014-01-14 듀크 유니버시티 Ｃｄ２０-특이적 항체 및 이를 이용한 방법
MXPA05012464A (es) 2003-05-21 2006-01-30 Novartis Ag Combinacion de inhibidores de deacetilasa de histona con agentes quimioterapeuticos.
EP1491188A1 (en) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
EP1663194B1 (en) * 2003-08-26 2010-03-31 Merck HDAC Research, LLC Use of SAHA for treating mesothelioma
JP2007504131A (ja) 2003-08-29 2007-03-01 エートン ファーマ インコーポレーティッド 癌の組み合わせ処置法
EP1689445B1 (de) * 2003-11-14 2015-02-25 Per Sonne Holm Neue verwendung von adenoviren und dafür codierende nukleinsäuren
CA2590257A1 (en) * 2003-11-14 2005-06-09 Per Sonne Holm Novel adenoviruses, nucleic acids that code for the same and the use of said viruses
US20070009956A1 (en) 2003-12-30 2007-01-11 Council Of Scientific And Industrial Research Arginine hydrochloride enhances chaperone-like activity of alpha crystallin
GB0401876D0 (en) * 2004-01-28 2004-03-03 Vereniging Het Nl Kanker I New use for cancer antigen
ATE437370T1 (de) * 2004-02-27 2009-08-15 Us Gov Health & Human Serv Pharmakodynamische tests mit durchflusszytometrie
DE602004014723D1 (de) * 2004-04-30 2008-08-14 Desitin Arzneimittel Gmbh Histondeacetylase-Inhibitor enthaltende Formulierung zur zweiphasigen Freisetzung
EP2476427B1 (en) 2004-08-02 2018-01-17 Zenyth Operations PTY. Ltd. A method of treating cancer comprising a VEGF-B antagonist
EP1787657A1 (en) * 2004-08-06 2007-05-23 Ono Pharmaceutical Co., Ltd. Therapeutic agent for psychoneurotic disease
JP4946861B2 (ja) * 2004-08-09 2012-06-06 アステラス製薬株式会社 ヒストンデアセチラーゼ（ｈｄａｃ）の阻害活性を有するヒドロキシアミド化合物
US8889742B2 (en) * 2004-11-30 2014-11-18 The Trustees Of The University Of Pennsylvania Use of HDAC and/or DNMT inhibitors for treatment of ischemic injury
FR2879204B1 (fr) 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
WO2006070024A2 (de) * 2004-12-31 2006-07-06 Per Sonne Holm E1 -minus adenoviren und deren verwendung
CA2594477C (en) * 2005-01-21 2016-07-12 Astex Therapeutics Limited Pharmaceutical compounds
EP2946810A1 (en) * 2005-02-03 2015-11-25 TopoTarget UK Limited Combination therapy using an HDAC inhibitor and Vincristine for treating cancer
US20060229237A1 (en) * 2005-04-07 2006-10-12 Yih-Lin Chung Treatment of gastrointestinal distress
GB0509225D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
CN102579417B (zh) * 2005-05-13 2014-11-26 托波塔吉特英国有限公司 Hdac抑制剂的药物制剂
EP1743654A1 (en) * 2005-07-15 2007-01-17 TopoTarget Germany AG Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
CA2619568A1 (en) * 2005-08-19 2007-03-01 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Topical formulations of histone deacetylase inhibitors and methods of using the same
EP1940767A2 (en) * 2005-09-07 2008-07-09 Plexxikon, Inc. Pparactive compounds
WO2007049262A1 (en) 2005-10-27 2007-05-03 Berand Limited Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders
EP2361619A1 (en) * 2005-11-10 2011-08-31 TopoTarget UK Limited Histone deacetylase (hdac) inhibitors (pxd-101) alone for the treatment of hematological cancer
US8445198B2 (en) * 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
NZ571357A (en) * 2006-02-22 2010-11-26 4Sc Ag Indolopyridines as EG5 kinesin modulators
AU2007217562A1 (en) * 2006-02-22 2007-08-30 4Sc Ag Indolopyridines as EG5 kinesin modulators
GB0606096D0 (en) 2006-03-27 2006-05-03 Cbmm Sa Screening method
EP1839656A1 (en) * 2006-03-31 2007-10-03 TopoTarget Germany AG Use of valproic acid for the topical treatment of mild to moderate acne vulgaris
JP2009536186A (ja) * 2006-05-08 2009-10-08 アステックス・セラピューティクス・リミテッド 癌処置のためのジアゾール誘導体の医薬組合せ
EP2040731A4 (en) * 2006-06-09 2010-05-19 Merrion Res Iii Ltd SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING AN ACTIVATOR
WO2008011603A2 (en) * 2006-07-20 2008-01-24 Wisconsin Alumni Research Foundation Modulating notch1 signaling pathway for treating neuroendocrine tumors
US20080242648A1 (en) * 2006-11-10 2008-10-02 Syndax Pharmaceuticals, Inc., A California Corporation COMBINATION OF ERa+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
WO2008090534A1 (en) 2007-01-26 2008-07-31 Berand Limited Methods and compositions for inhibition of excessive weight gain, reduction of inappropriate eating behaviours and inhibition of binge eating for the treatment of obesity
WO2008094319A2 (en) * 2007-02-01 2008-08-07 The Board Of Regents Of The University Of Texas Sytem Methods and compositions of trail-death receptor agonists/activators
US8012695B2 (en) * 2007-02-14 2011-09-06 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to promoter regulation by MUC1 and KLF proteins
WO2008136838A1 (en) * 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
CA2726734C (en) * 2007-06-06 2014-10-07 University Of Maryland, Baltimore Hdac inhibitor ms-275 and aromatase inhibitors for the treatment of cancer
US20090246198A1 (en) * 2008-03-31 2009-10-01 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
US20090270497A1 (en) * 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
US8637554B2 (en) * 2008-05-07 2014-01-28 The Trustees Of The University Of Pennsylvania Methods for treating thyroid cancer

Also Published As

Publication number Publication date
US20100286279A1 (en) 2010-11-11
MX2010003230A (es) 2010-04-07
JP2010540426A (ja) 2010-12-24
US8642809B2 (en) 2014-02-04
EP2203421A2 (en) 2010-07-07
HK1145831A1 (en) 2011-05-06
WO2009040517A3 (en) 2009-06-25
EP2203421B1 (en) 2014-05-07
CN101868446A (zh) 2010-10-20
WO2009040517A2 (en) 2009-04-02
CA2700173A1 (en) 2009-04-02

Similar Documents

Publication Publication Date Title
EP2203421B1 (en) Methods of synthesis of certain n-hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide compounds
CN108779186A (zh) 一种改进的制备舒更葡萄糖的方法
WO2009056029A1 (en) Purification method of pemetrexed salts,sodium salts and disodium salts
ES2984149T3 (es) Método de síntesis de cariprazina
ES2254522T3 (es) Procedimiento de produccion de acido r(+) alfa-lipoico.
KR20210005042A (ko) 엘라미프레티드의 합성에 유용한 결정질 디펩티드
WO2009119785A1 (ja) エチニルチミジン化合物の精製方法
HK1145831B (en) Methods of synthesis of certain n-hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide compounds
CA2615691C (en) Process for the preparation of crystalline perindopril
CN104774150B (zh) 一种双醋瑞因晶体及其制备方法
KR101247137B1 (ko) Ｎ-[ｏ-(ｐ-피발로일옥시벤젠술포닐아미노)벤조일]글리신의 신규 제조 방법 및 그 모노나트륨염ㆍ4 수화물의 동결 건조 제제의 제조 방법
ES2312162T3 (es) Procedimiento para la obtencion de una sal de valsartan util para la preparacion de valsartan.
JP2002114755A (ja) メシル酸カモスタットの製造方法
HU230144B1 (hu) Eljárás quetiapin előállítására
ES2868633T3 (es) Método de aislamiento y purificación de la naltrexona
JP4402361B2 (ja) 塩酸エピナスチンの結晶多形
JPH11180948A (ja) Ｓ−（１，２− ジカルボキシエチル） グルタチオンの製造法
JPH0142273B2 (enExample)
JP5914246B2 (ja) ブリンゾラミドの精製方法
JP6227963B2 (ja) モンテルカストジプロピルアミン塩の結晶を製造する方法
JP4475573B2 (ja) リシノプリル２水和物の製造方法
KR101366706B1 (ko) Ｎ-[ｏ-(ｐ-피발로일옥시벤젠술포닐아미노)벤조일]글리신의 신규 제조 방법 및 그 모노나트륨염ㆍ4 수화물의 동결 건조 제제의 제조 방법
CN118084735A (zh) O-[2-[[叔丁氧羰基]氨基]乙基]-n-[芴甲氧羰基]-l-酪氨酸的光延合成法
JP2002316952A (ja) 光学活性２−フェノキシプロピオン酸の光学精製方法
ITMI20090396A1 (it) Processo di preparazione di tigeciclina

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130826

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240913

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240913

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240913

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250919

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250919